home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Viatris Inc. - Common Stock (NQ:VTRS)

13.29 -0.12 (-0.86%)

Streaming Delayed Price Updated: 12:22 PM EDT, Apr 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022 ↗

November 10, 2022

Upgrades

Via Benzinga

4 Analysts Have This to Say About Viatris ↗

November 10, 2022

Viatris (NASDAQ:VTRS) has observed the following analyst ratings within the last quarter:

Via Benzinga

Want to Collect a High Dividend Every Month? Buy These 3 Stocks ↗

November 10, 2022

Together, these stocks will ensure you're receiving a dividend each month of the year.

Via The Motley Fool

Ocuphire Pharma Shares Jump After Global Licensing Pact For Nyxol Eye Drops ↗

November 08, 2022

Via Benzinga

Why Viatris Stock Is Jumping Today ↗

November 07, 2022

Investors are applauding a key step in Viatris' plans to return to growth.

Via The Motley Fool

Why Viatris Shares Are Soaring Higher ↗

November 07, 2022

Viatris Inc (NASDAQ: VTRS) shares are trading higher by 16.80% to $11.33 Monday morning after the company announced it will acquire Oyster Point Pharma. What Happened?

Via Benzinga

Viatris' Mylan Recalls One Lot Of Octreotide Acetate Injection Due To Glass Particulates ↗

October 26, 2022

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)

November 08, 2022

From Brodsky & Smith LLC

Via GlobeNewswire

Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday ↗

November 08, 2022

U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Oyster Point Pharma (NASDAQ: OYST) Enters Into Agreement to be Acquired by Viatris (NASDAQ: VTRS) For $11 Per Share Plus CVR Up to $2.00 Per Share

November 07, 2022

Oyster Point Pharma, Inc. (NASDAQ: OYST) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development

Via Spotlight Growth

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022 ↗

November 08, 2022

Upgrades

Via Benzinga

Viatris Bolsters Its Ophthalmology Franchise With Oyster Point Pharma Deal, Shares Surge ↗

November 07, 2022

Via Benzinga

IAA Stock Moves as Ritchie Bros Acquires Company in $7.3 Billion Deal ↗

November 07, 2022

IAA (IAA) stock is moving on Monday thanks to a massive acquisition $7.3 billion deal with Ritchie Bros Auctioneers (RBA).

Via InvestorPlace

Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday ↗

November 08, 2022

Gainers

Via Benzinga

Viatris (VTRS) Stock Pops 17% on Acquisition News ↗

November 07, 2022

One press release with numerous positive catalysts is prompting some VTRS stock traders to load up on the shares today.

Via InvestorPlace

Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session ↗

November 07, 2022

Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870.

Via Benzinga

What Does Sunshine Biopharma's Acquisition Of Nora Pharma Mean For The Generic Prescription Drugs Market? ↗

November 07, 2022

The generic drug market has been growing since 1984 when the Hatch-Waxman Act encouraged manufacturing generics and developed a framework to regulate them.

Via Benzinga

Cramer On This Stock Up 138% Year-To-Date: 'Santa Can't Afford That Coal, It's Going Up Too Much' ↗

November 07, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Cano Health Inc (NYSE: CANO).

Via Benzinga

Oyster Point Pharma, a Leading Ophthalmology-Focused Biopharmaceutical Company, to be Acquired by Viatris

November 07, 2022

From Oyster Point Pharma, Inc.

Via GlobeNewswire

Recap: Viatris Q3 Earnings ↗

November 07, 2022

Viatris (NASDAQ:VTRS) reported its Q3 earnings results on Monday, November 7, 2022 at 06:50 AM. Here's what investors need to know about the announcement. Earnings Viatris beat estimated earnings by...

Via Benzinga

How To Attend Viatris Q3 2022 Earnings Conference Call ↗

November 01, 2022

Viatris (NASDAQ:VTRS) will host a conference call at 08:30 AM ET on November 7, 2022, to discuss Q3 2022 earnings results. How to Attend Viatris (VTRS) Conference Call Follow this link to access the...

Via Benzinga

3 Feel-Good Ways to Lose Lots of Money in the Bear Market ↗

October 26, 2022

All three are liable to happen when you lose your focus on investing for the long term.

Via The Motley Fool

Recent Stock Purchase Update For October 2022 ↗

October 24, 2022

As you may know by now, I make a stock purchase every single month no matter what is going on in the world and despite the doom and gloom headlines. Let's take a look at what I've added to my portfolio...

Via Talk Markets

Earnings Scheduled For November 7, 2022 ↗

November 07, 2022

Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.

Via Benzinga

3 Healthcare Stocks That Are Too Cheap to Ignore ↗

October 22, 2022

They all offer attractive dividends, too.

Via The Motley Fool

3 Dirt-Cheap Stocks to Buy Sooner Rather Than Later ↗

October 22, 2022

Procrastination could be problematic with these three bargain stocks.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022 ↗

October 21, 2022

Upgrades

Via Benzinga

Novartis Fails To Prevent Generic Competition For Its Blockbuster Multiple Sclerosis Drug ↗

October 14, 2022

The U.S. Supreme Court rejected Novartis AG's (NYSE: NVS) effort to block the launch of generic versions of its multiple sclerosis drug Gilenya.

Via Benzinga

US Supreme Court Turns Away Biogen's Last Effort To Reinstate Tecfidera Patent ↗

October 03, 2022

The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

September 22, 2022

On Thursday, 1076 companies hit new 52-week lows.

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com